New combo therapy offers hope for advanced bile duct cancer patients
NCT ID NCT07291063
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with advanced bile duct cancer that cannot be removed by surgery. It tests whether adding immunotherapy drugs (anti-PD-1/PD-L1 antibodies) to standard chemotherapy (gemcitabine and cisplatin) is safe and works better at shrinking tumors and delaying cancer growth. About 50 adults will take part, and researchers will monitor side effects and how long the cancer stays under control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongshan Hospital Fudan university
RECRUITINGShanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new test could reveal how radiation affects the liver
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a smart drug home in on Hard-to-Treat GI cancers?
- Can matching drugs to tumor genes beat biliary cancer?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Web tool aims to empower rare cancer patients in genomic choices